Kelly has over 25 years’ experience working in the insurance industry in Australia and the UK. She started as a graduate with an insurance broker in Melbourne working on the architect scheme for the Royal Australian Institute of Architects (RAIA).
Kelly moved to London in 1999, working with various Lloyds insurance brokers on the Irish solicitor scheme, the scheme for the Association of Consulting Engineers, and spent 14 years at Miller Insurance placing Life Science and Biotech business. She handled many difficult to place risks for pharmaceutical companies, and specialised in complex global clinical trial placements. Kelly also has experience with Medical Malpractice, Intellectual Property, Professional Indemnity, General Liability, Product Recall, and SME insurance classes for startups to listed companies.
Kelly moved back to Melbourne in 2016 with her family and commenced underwriting at ProRisk, Dual, and most recently at Avatar Brokers for four years placing Life Science policies. This work with ASX clients and difficult to place risks has given her solid experience in assisting brokers with their clients’ demands. She always aims to provide excellent customer service and works in partnership with brokers.
You can find Kelly enjoying music festivals or concerts when she is not working, or attending spin classes, walking her Italian greyhound, trying out new cafes and restaurants, and attending many sporting events. She is an avid English Premier League fan following LFC (Liverpool Football Club) and enjoying time with family.
Kelly has over two decades of experience within the insurance industry both in Australia and the UK. The introduction to the Life Science sector arose from working in London with a leading Lloyds insurance broker and exposure to negotiating UK and global insurance policies for numerous large pharmaceutical companies.
Kelly has in depth understanding of the parties involved in a clinical trial, the cycle of a clinical study to product stage, and other insurance requirements as clients commercialise their products.
